• To review the published data on predisposing risk factors for cancer treatment-induced haemorrhagic cystitis (HC) and the evidence for the different preventive and therapeutic measures that have been used in order to help clinicians optimally define and manage this potentially serious condition.
• Despite recognition that HC can be a significant complication of cancer treatment, there is currently a lack of UK-led guidelines available on how it should optimally be defined and managed.
• A systematic literature review was undertaken to evaluate the evidence for preventative measures and treatment options in the management of cancer treatment-induced HC.
• There is a wide range of reported incidence due to several factors including variability in study design and quality, the type of causal agent, the grading of bleeding, and discrepancies in definition criteria.
• The most frequently reported causal factors are radiotherapy to the pelvic area, where HC has been reported in up to 20% of patients, and treatment with cyclophosphamide and bacillus Calmette-Guérin, where the incidence has been reported as up to 30%.
• Mesna (2-mercaptoethane sodium sulphonate), hyperhydration and bladder irrigation have been the most frequently used prophylactic measures to prevent treatment-related cystitis, but are not always effective.
• Cranberry juice is widely cited as a preventative measure and sodium pentosanpolysulphate as a treatment, although the evidence for both is very limited.
• The best evidence exists for intravesical hyaluronic acid as an effective preventative and active treatment, and for hyperbaric oxygen as an equally effective treatment option.
Introduction
Haemorrhagic cystitis (HC) can be either acute or chronic, and be caused by chemotherapeutic drugs, radiation therapy (RT), or exposure to chemicals, e.g. dyes or insecticides [1] . In transplantation settings, HC is typically associated with haematopoietic stem cell transplant (HSCT), but can also occur, albeit rarely, in solid organ recipients [2] . It is thought that a defect in the glycosaminoglycan (GAG) layer, which coats the uroepithelium and provides the initial barrier for physiological protection, may be the first step in its development [3] . Once injured or defective, the GAG layer loses its barrier properties, becomes permeable, and allows the inflammatory and hypersensitisation cycle to thrive [3] .
With a tendency towards more aggressive treatment of cancer, including the use of HSCT, chemical-and RT-induced HC can be considered an increasingly important clinical issue, not least because it is a challenging condition to treat. However, few epidemiological studies have been undertaken and therefore, the exact prevalence is unknown. Treatment can be problematic, especially in elderly patients who may be frail and have comorbidities [4] , and because the condition often responds inadequately to the usual symptomatic therapies. In severe cases, HC is associated with significant morbidity, prolonged hospitalisation and occasional mortality, and may require more aggressive measures, e.g. supravesical urinary diversion, vesical artery selective embolization, and cystectomy [5] . Furthermore, as the global burden of cancer is forecast to rise, primarily due to ageing and growth of the world's population [6] , it is likely that the incidence of HC will rise too because of the increasing use of RT and chemotherapy. However, there is currently a lack of consensus about the best treatment for patients with chemical-and RT-induced HC, as well as a lack of UK-led guidelines available on how it should optimally be defined and managed.
The aim of the present article is to review the predisposing risk factors for chemical-and RT-induced HC and the evidence for the different therapeutic and preventive measures that have been used to help clinicians better manage this potentially disabling condition.
Methods
A comprehensive literature search was undertaken in PubMed to retrieve studies and case reports, published in English, relating to the treatment of chemical-and RT-induced HC from 1980 to September 2012. The search was conducted using a comprehensive search strategy, including the terms 'haemorrhagic cystitis' , 'chemical cystitis' , 'radiation cystitis' in combination with 'risk factors' , 'chemotherapeutic drugs' , 'hyaluronic acid' , 'sodium hyaluronate' , 'hyperbaric oxygen' , 'mesna' , 'hyperhydration' , 'bladder irrigation' , 'pentosanpolysulphate' , 'oestrogen' , 'recombinant factor VII' , 'formalin' , and 'prostaglandin' . The search results were supplemented by review of the bibliographies of key articles for additional studies, inclusion of relevant abstracts presented at key meetings, as well as expert input, to help ensure the capture of all pertinent data.
Results

Incidence and Reported Predisposing Risk Factors
HC has multiple potential causes, including chemical toxins and radiation. As well as variability in the propensity of the causative factor to induce HC, differences in definition criteria are in part responsible for the wide range of reported incidences [7] , with some degree of HC affecting up to 100% of patients in some studies. The available scoring systems for the severity of toxicity also use variable criteria, further complicating the comparative assessment of agents and studies in which they are used.
HC has a spectrum of manifestations that range from non-visible (or microscopic) haematuria to gross (visible) 
Prevention and Treatment of HC
Hyperhydration and Continuous Bladder Irrigation
Mesna, hyperhydration and bladder irrigation appear to be the most frequently used prophylactic measures for treatment-related HC, with varying, often disappointing, results [44-52] (Table 3) . For continuous bladder irrigation, it is vital that clots are evacuated before therapy as the success of subsequent irrigation often depends upon the thoroughness of this procedure [5] .
Turkeri et al. [45] reported that continuous bladder irrigation significantly decreased the frequency of HC in patients receiving busulfan and cyclophosphamide as a preparative regimen for bone marrow transplant (BMT) compared with no bladder irrigation (23% vs 53%, respectively; P < 0.004). Similar findings were reported by Hadjibabaie et al.
[44] in a non-randomised, controlled study of HSCT patients who received mesna, hydration, and alkalisation regimens. HC occurred in fewer patients who received continuous bladder irrigation than in those who did not (32% vs 50%, respectively; P = 0.11). Continuous bladder irrigation was also found to significantly reduce the mean duration of HC (10 vs 18 days; P = 0.02) and the duration of hospitalisation (30.2 vs 39.6 days; P < 0.001) [44] . In a study by Trotman et al.
[49], the overall incidence of HC in HSCT patients using a prophylactic regimen of hyperhydration and forced diuresis was 18.2%.
Treatment of chemical-and radiation-induced haemorrhagic cystitis
Grade III or IV HC, based on the system devised by Droller et al.
[9], occurred in 3.4% of patients. Of potential significance, a randomised study by Atkinson et al. [48] showed that bladder irrigation did not minimise the risk of HC in patients receiving allogeneic BMT as a treatment for haematological malignancy.
Mesna
Other routine methods of preventing chemical-induced HC include the use of mesna, which was specifically developed to bind acrolein in the urine. Mesna has been extensively investigated in the management of cyclophosphamide-and ifosfamide-induced HC with variable results [15, [50] [51] [52] [53] [54] [55] [56] [57] . It is also unclear whether the addition of mesna therapy to hyperhydration provides greater protection in BMT patients who are exposed to cyclophosphamide. Shepherd et al. [51] concluded that both approaches were equally effective in preventing cyclophosphamide-induced HC in BMT patients. Nevertheless, HC was still seen in 33% of patients who received mesna prophylaxis [51] . Similar findings were reported by Vose et al.
[52] in a prospective randomised trial of mesna and continuous bladder irrigation. Whilst the overall incidence of haematuria of any grade was significantly higher in the bladder-irrigation group compared with the mesna group (76% vs 53%; P = 0.007), the incidence of grade III and IV haematuria was the same in both treatment groups (18%; statistically non-significant) [ Chondroitin sulphate
Most of the published studies on the use of chondroitin sulphate have evaluated its use in the treatment of interstitial cystitis/painful bladder syndrome. Based on animal studies, Hazewinkel et al. [59] hypothesised that prophylactic installation of chondroitin sulphate in patients undergoing RT for gynaecological malignancies may limit the risk of RT cystitis symptoms. In their pilot study, the efficacy of chondroitin sulphate was evaluated in 20 patients; 10 received weekly intravesical installations and 10 were controls. The acceptability of instillations and bladder pain were evaluated using a visual analogue scale (VAS). The patients receiving chondroitin sulphate reported less bothersome symptoms and the treatment was well tolerated. The instillations also appeared to reduce overactive bladder symptoms during the Further data from a prospective study by Sommariva et al. [61] show that sodium hyaluronate also relieves the symptoms of chemo-or RT-induced cystitis. In all, 69 consecutive patients who had symptoms of cystitis after RT for prostatic cancer or after intravesical BCG or mitomycin C were given intravesical instillations of sodium hyaluronate and cortisone. Overall, 67 (97%) patients reported complete relief of dysuria and pain, which was assessed using a VAS. Patients with chemicalinduced cystitis were found to respond slightly better than those who had RT-induced cystitis. Shao et al. [60] have also shown that intravesical instillation of sodium hyaluronate is as effective as hyperbaric oxygen (HBO) therapy in the treatment of RT-induced cystitis. In this randomised study of 36 patients with pelvic malignancies, there was no statistical difference between the two groups in the improvement rate (complete response and partial response) at 6, 12 and 18 months after treatment. However, whilst the decrease in frequency vs baseline was significant in both groups 6 months after treatment, it was significant only in the sodium hyaluronate group 12 months after therapy. This treatment strategy was well tolerated and resulted in a sustained decrease of bladder bleeding, pelvic pain and frequency of voiding for ≥12 
Alum irrigation
Alum irrigation was first reported in 1982, when it was successfully used to treat six patients with massive bladder haemorrhage secondary to RT cystitis, bladder carcinoma and HC [79] . Since then, there have been several reports on the use of alum irrigation in the management of cyclophosphamideand RT-induced HC with varying degrees of success [68, 80, 81] . There have also been several case reports of aluminium toxicity after intravesical alum irrigation for HC in children [82] [83] [84] ; therefore, vigilance is needed to avoid these toxic effects [68] .
Systemic Treatments
Systemic treatments, e.g. HBO, oestrogen, sodium pentosanpolysulphate, recombinant factor VII or VIII, and aminocaproic acid have been used with some success in the treatment of HC (Table 5) Oestrogen Several small series and case reports have reported that HC secondary to RT or cyclophosphamide therapy has been successfully treated with oestrogen [90, 91, 101, 102] . Heath et al. [90] reported that eight out of 10 children and adolescents treated initially with intravenous oestrogen and then oral oestrogen after 2 or 3 days had a significant reduction in their symptoms after commencing therapy. In another series, Ordemann et al. [91] reported that, after treatment with oral oestrogen, haematuria resolved in two of four adult patients with mild HC and four of five patients with severe HC. In all the case reports, oestrogen therapy appeared to be generally well tolerated [90, 91, 101, 102] . Potential adverse effects of long-term exposure to oestrogens include an increased risk of cancer [91] .
Sodium pentosanpolysulphate
Sodium pentosanpolysulphate is a semi-synthetic GAG similar to heparin with anticoagulant properties and fibrinolytic effects [5] . This treatment has had some success in small series and case reports in treating patients who have developed HC secondary to RT or cyclophosphamide therapy [103] [104] [105] , but the patient series have been limited in size. In a larger study, Sandhu et al.
[39] retrospectively reviewed the pharmacy records of 60 patients with HC; of these patients, 53 had received radical RT for pelvic malignancy and seven had received systemic cyclophosphamide. After treatment with sodium pentosanpolysulphate, the dose was gradually reduced in 21 patients and treatment was discontinued in a further 10 patients because the haematuria stopped completely. Although the safety and efficacy of sodium pentosanpolysulphate has not been established in paediatric patients [5] , a recent retrospective case note review of children with HC after stem cell transplant/chemotherapy reported that early identification, avoidance of urethral catheterisation, and use of sodium pentosanpolysulphate significantly reduces blood transfusion requirements and mortality from HC [103] .
Recombinant factor VIIa/factor XIII Several case reviews and case reports have suggested a potential role for recombinant factor VII or XIII in the treatment of cyclophosphamide-and RT-induced HC [106] [107] [108] [109] . Ashrani et al. [92] reported the results of a pilot study using high-dose activated recombinant factor VII in seven adult patients with severe refractory HC and prior exposure to cyclophosphamide or ifosfamide. Six of the seven patients achieved a response: four complete responses and two partial responses. Although there was no serious adverse event, the response duration was found to be only temporary. In a multicentre, randomised trial, Pihusch et al. [110] reported no aggregate benefit in the treatment of various haemorrhagic complications, including HC, with recombinant factor VII after HSCT, although post hoc analysis showed an improvement in the control of bleeding with increased dose.
Aminocaproic acid
Aminocaproic acid has proved to be successful in one small study of 37 patients with intractable bladder haemorrhage, most of whom had RT-or cyclophosphamide-induced cystitis.
No side-effects were observed [111] .
Other Therapeutic Approaches
Anecdotally, patients with chemical or RT-induced cystitis are often advised to try cranberry juice, and in some centres, it is considered the 'gold standard' of treatment. A recent systematic review and meta-analysis of 13 randomised controlled trials showed that cranberry-containing products are associated with a protective effect against UTIs [112] . The mechanism is thought to be the adhesion of bacteria to uroepithelial cells by proanthocyanidins, a compound present in cranberry [113] . Although earlier studies showed statistically insignificant or negative results [114, 115] , data from a recent study show that the beneficial effects of cranberry extract in prevention of LUTS can be seen in patients with prostate cancer with acute bladder damage associated with high-dose RT [113] . The authors propose that because of its strong antioxidant properties, it is possible that cranberry could attenuate actinic damage to the bladder mucosa, reducing the inflammatory process and, as a consequence, its symptoms. However, further studies are warranted [113] .
Over the last 15 years, numerous other therapeutic approaches have been tried and have shown some benefit in the treatment of HC. These include: botulinum toxin A bladder injections in patients with refractory RT-induced cystitis and BCG-induced chemical cystitis [116] , intravesical recombinant human granulocyte-macrophage colony-stimulating factor [117] , neodymium:YAG (yttrium-aluminium-garnet) laser therapy [118, 119] , and WF10 (tetrachlorodecaoxide i.v. solution) therapy [120] . However, the role of many of these treatment methods remains investigational.
Surgical Approaches to HC
In cases where medical treatment has failed to control HC, surgical intervention may be the treatment of last resort [1, 121] . Several options have been used, including cutaneous ureterostomy [121] , cystoscopy and diathermy [122] , vesical artery embolization [123] [124] [125] , and supravesical urinary diversion with, or without, radical cystectomy [43, 126] . Although successful resolution after the various interventions has been reported in a limited number of case studies [10, [121] [122] [123] [124] [125] , major surgical procedures in these cases can be associated with high morbidity and mortality [125] , as well as leading to permanent changes to the anatomy and function of the genitourinary system [10, 127] .
Discussion
HC remains a significant complication after high-dose chemo-RT, especially in conjunction with HSCT [7] . However, there is a wide range of reported incidence due to several factors including: the type of causal agent, the grading of bleeding, and discrepancies in definition criteria [7, 23] . Although HC is a potentially severe complication, which can cause significant morbidity and considerable expense due to prolonged hospitalisation [18] , there is no published national or international consensus on the optimal therapeutic strategy. The present review has highlighted that the evidence base is currently limited for the various treatment methods used to prevent and/or treat HC. Most of the reported studies are either uncontrolled, non-randomised studies, or small case series or case reports, and involve few patients who have had several different treatment methods. The two therapeutic approaches with seemingly the best available evidence are HBO therapy in the treatment of HC and sodium hyaluronate in the prevention and treatment of HC. [19] unexpectedly found that both these prophylactic measures increased the frequency of HC after HSCT, particularly when mesna was administered with busulfan.
Therefore, it appears that the standard preventive protocols do not always satisfactorily protect the patient from bladder injury [128] .
HBO therapy has been shown to have efficacy in the treatment of patients in whom other forms of management have failed, with few side-effects [39, 86, 87, 97] ; although the number of HBO treatments administered and characteristics of hyperbaric exposure differs among the various reports. A randomised controlled study on the use of HBO for the treatment of RT-induced HC is currently recruiting patients [129] . Whilst HBO therapy appears an effective treatment method for HC, the practicalities of longer-term administration and access/availability issues are potential barriers to its more widespread use.
In recent years, GAG-replenishment therapy has widened the therapeutic options for patients with HC [130] . Intravesical installation of sodium hyaluronate has been used successfully in the prevention and treatment of chemical-and RT-induced HC. Studies have shown that sodium hyaluronate can significantly relieve bleeding, pain and dysuria and is well tolerated [61-63,72]. Data from a small randomised study have shown that it is at least as effective as HBO at treating RT-induced HC [60] . The positive efficacy results and apparent lack of side-effects make sodium hyaluronate a potentially attractive option for the prevention and treatment of HC secondary to RT and chemotherapy, particularly in patients already catheterised.
Several other therapeutic and preventive measures have also been used in the treatment of HC, e.g. intravesical prostaglandins, chondroitin sulphate, oestrogen therapy, and sodium pentosanpolysulphate. Whilst there has been some reported success with these therapies [39, 58, 59, 91] , it is difficult to draw any firm conclusions due to the generally poor quality of the available evidence.
A systematic review and meta-analysis of interventions for preventing HC in patients undergoing HSCT is currently being undertaken by the Cochrane Collaboration and it is hoped that this will provide more conclusive evidence on the optimum treatment [131] . The lack of robust data and variability in treatment strategies used highlights the need for further research, as well as best practice guidance and consensus on the management of this complication, which can often be challenging to treat.
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